Moncef Slaoui

Moncef Slaoui is currently Chairman at Altesa BioSciences, Inc., Chairman at Arcturus Therapeutics Holdings, Inc. starting 2025, Director at Biotechnology Innovation Organization, Director at Zephyr AI, Inc., Director at Monopteros Therapeutics, Inc., and Venture Partner at Medicxi Ventures (Jersey) Ltd. since 2017.
Former positions include Director and Chairman-Research & Development at Genelabs Technologies, Inc., Director and Chairman-Global Research & Development at GSK Plc from 2006 to 2017, Chairman at Vaxcyte, Inc. from 2018 to 2021, Chairman at Galvani Bioelectronics Ltd. from 2016 to 2021, Director at International AIDS Vaccine Initiative, Inc., Independent Director at Lonza Group AG in 2020, Director at Agency for Science, Technology & Research, Director at Pharmaceutical Research & Manufacturers of America, Director and Strategic Advisor at Longwood Fund Management LLC, Director at ModernaTX, Inc., Director at PhRMA Foundation from 2008 to 2016, Director at Intellia Therapeutics, Inc. in 2017, Director at Artizan Biosciences, Inc., Independent Non-Executive Director at Moderna, Inc. from 2017 to 2020, Immunology Professor at the University of Mons Hainaut, and Professor at Université de Mons.
Education includes graduate studies at Tufts University, a doctorate from Université Libre de Bruxelles, an MBA from International Institute for Management Development conferred in 1998, and graduate studies at Harvard Medical School.